Research Letter

Pediatric Croup during the COVID-19 Omicron Variant Surge

Emine M. Tunç, MD
Cassandra Koid Jia Shin, MB BCh BAO
Etiowo Usoro, MHI
Siobhan E. Thomas-Smith, MD
Russell T. Migita, MD
Indi Trehan, MD MPH DTM&H
Ashley E. Keilman, MD

Author Affiliations: Seattle Children’s Enterprise Analytics, Seattle Children’s Hospital, Seattle, Washington (Usoro); Division of Pediatric Emergency Medicine, University of Washington, Seattle, Washington (Tunç, Koid Jia Shin, Thomas-Smith, Migita, Trehan, Keilman)

Corresponding Author: Ashley Keilman, MD, Division of Pediatric Emergency Medicine, 4800 Sand Point Way NE, M/S MB.7.520, Seattle, WA 98105

Author Contributions:
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: Usoro, Trehan.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Usoro, Trehan.
Obtained funding: None.
Administrative, technical, or material support: Migita, Keilman.
Supervision: Migita, Trehan, Keilman.

Conflict of Interest Disclosures: None reported.

Acknowledgments: We thank Pavitra Roychoudhury, PhD, Department of Laboratory Medicine and Pathology, University of Washington, for her help in accessing local SARS-CoV-2 surveillance data.

Word Count: 600
Abstract

Croup is a common upper respiratory disease usually associated with parainfluenza virus, resulting in stridor, hoarse voice, barky cough, and variable respiratory distress. Here we examine the data at our center confirming a sharp increase in cases of croup associated with the Omicron variant. Data was retrospectively extracted from patient charts among those seen in the Emergency Department at Seattle Children’s Hospital. Inclusion criteria were patients who were assigned a diagnosis containing “croup” during either 5/30/2021-11/30/2021, a time period correlating with predominance of the COVID-19 Delta variant (B.1.617.2), or the initial phase of the Omicron variant surge (12/1/2021-1/15/2022). Contemporaneous publicly available local data on the proportion of SARS-CoV-2 samples in surrounding King County, Washington, with spike gene target failure on TaqPath PCR assays was used as a proxy for the proportion of infections caused by the Omicron variant. A total of 401 patients were diagnosed with croup during the Delta surge and 107 patients were diagnosed with croup during the Omicron surge. Patients who presented during the Omicron surge were more likely to test positive for COVID-19 (48.2% vs 2.8%, p < 0.0001). Children with a clinical diagnosis of croup during the Omicron surge were more likely to be prescribed racemic epinephrine as part of their care (21.5% vs 13.0%, p = 0.032). There were no differences in presenting age, rate of admission, rate of return to the ED within 72 hours, or admission among those who returned within 72 hours. During the Omicron surge, the incidence of croup nearly doubled compared to the rate in prior months, while at the same time the number of cases of parainfluenza virus identified decreased. Consistent with prior case reports, we have identified a sharp rise in cases of croup seen in our pediatric ED in parallel with the replacement of the SARS-CoV-2 Delta variant by Omicron as the dominant variant in our community.
Introduction

Croup (viral laryngotracheitis) is a common upper respiratory disease usually associated with parainfluenza virus, resulting in stridor, hoarse voice, barky cough, and variable respiratory distress.\(^1\) Sporadic case reports have suggested an association between SARS-CoV-2 and croup.\(^2\)-\(^5\) Early \textit{ex vivo} studies suggest that the Omicron variant (B.1.1.529) of SARS-CoV-2 replicates more rapidly in higher airways than previous lineages.\(^6\) Here we examine the data at our center confirming a sharp increase in cases of croup associated with the Omicron variant.

Methods

High-level data was retrospectively extracted from patient charts among those seen in the Emergency Department (ED) at Seattle Children’s Hospital (SCH), an academic, quaternary-care, free-standing children’s hospital with more than 50,000 annual ED visits prior to the COVID-19 pandemic. Inclusion criteria were patients who were assigned a diagnosis containing “croup” during either 5/30/2021-11/30/2021, a time period correlating with predominance of the COVID-19 Delta variant (B.1.617.2), or the initial phase of the Omicron variant surge (12/1/2021-1/15/2022). Qualitative SARS-CoV-2 PCR testing from nasopharyngeal or mid-turbinate swabs were obtained at the discretion of the treating clinician, as were interventions such as racemic epinephrine and hospitalization. Contemporaneous publicly available local data on the proportion of SARS-CoV-2 samples in surrounding King County, Washington, with spike gene target failure on TaqPath PCR assays was used as a proxy for the proportion of infections caused by the Omicron variant (https://depts.washington.edu/labmed/covid19/#sequencing-information). This study was approved by the SCH Institutional Review Board.
Results

A total of 401 patients were diagnosed with croup during the Delta surge and 107 patients were diagnosed with croup during the Omicron surge. Patients who presented during the Omicron surge were more likely to test positive for COVID-19 (48.2% vs 2.8%, p < 0.0001) (Table). The rate of viral respiratory testing remained similar during both time periods; our testing capacity did not decrease until after 1/15/22. Children with a clinical diagnosis of croup during the Omicron surge were more likely to be prescribed racemic epinephrine as part of their care (21.5% vs 13.0%, p = 0.032). There were no differences in presenting age, rate of admission, rate of return to the ED within 72 hours, or admission among those who returned within 72 hours.

During the Omicron surge, we have seen that the incidence of croup nearly doubled compared to the rate in prior months, while at the same time the number of cases of parainfluenza virus identified decreased (Figure).

Discussion

Consistent with prior case reports, we have identified a sharp rise in cases of croup seen in our pediatric ED in parallel with the replacement of the SARS-CoV-2 Delta variant by Omicron as the dominant variant in our community. This increase is not temporally associated with the circulation of parainfluenza virus, and indeed Omicron has replaced parainfluenza as the predominant cause of viral croup at this time. Viral testing is not routinely recommended for
patients with croup; testing that was performed was for a wide variety of patients and indications, but we do believe our data is a reasonable proxy for local population prevalence. The end of the study period coincides with a change in our hospital practice due to test supply limitations and thus we are not able to see if this current trend continues with as much precision.

Children with croup during this time were more likely to receive racemic epinephrine, perhaps suggesting a more severe initial clinical presentation, but since treatment was up to individual clinician judgment and thus no definitive statements can be made in this regard. Based on admission rates and return visits, there is no data to support changing the current standard of care for individual patient management.

References

Table. Characteristics of croup patients in the Seattle Children’s Hospital Emergency Department during phases of the COVID-19 pandemic.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Delta Surge&lt;sup&gt;a&lt;/sup&gt; N = 401&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Omicron Surge&lt;sup&gt;b&lt;/sup&gt; N = 107&lt;sup&gt;c&lt;/sup&gt;</th>
<th>p-value&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>2.33 (1.42, 3.83)</td>
<td>2.25 (1.08, 3.62)</td>
<td>0.29</td>
<td></td>
</tr>
<tr>
<td>COVID status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detected</td>
<td>6 (2.8%)</td>
<td>27 (48.2%)</td>
<td>&lt; 0.0001</td>
<td>31.8 (12.7-80.2)</td>
</tr>
<tr>
<td>Negative</td>
<td>205 (97.2%)</td>
<td>29 (51.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not tested</td>
<td>190</td>
<td>51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Received racemic epinephrine</td>
<td>52 (13.0%)</td>
<td>23 (21.5%)</td>
<td>0.032</td>
<td>1.84 (1.06-3.18)</td>
</tr>
<tr>
<td>Admitted</td>
<td>15 (3.7%)</td>
<td>4 (3.7%)</td>
<td>&gt; 0.99</td>
<td>1.00 (0.35-2.85)</td>
</tr>
<tr>
<td>72-hr return to ED</td>
<td>12 (3.0%)</td>
<td>6 (5.6%)</td>
<td>0.23</td>
<td>1.93 (0.72-5.06)</td>
</tr>
<tr>
<td>72-hr return admission</td>
<td>3 (25.0%)</td>
<td>1 (16.7%)</td>
<td>&gt; 0.99</td>
<td>0.60 (0.04-5.19)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Time period when Delta variant was locally predominant: 5/30/2021 – 11/30/2021.

<sup>b</sup> Time period when Omicron variant was locally predominant: 12/1/2021 – 1/15/2022.

<sup>c</sup> Median (IQR) for age; n (%) for other variables.

<sup>d</sup> Wilcoxon rank sum test for age; Fisher's exact test for other variables.
Figure. Number of patients diagnosed with croup, parainfluenza incidence, and community prevalence of spike gene target failure for SARS-CoV-2 by PCR (7-day rolling averages).